Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

Mechanisms of Aging Vary with Developmental Stages in the Human Hematopoietic Trajectory

Laura Poisa-Beiro, Jonathan JM Landry, Michael Kardorff, Volker Eckstein, Laura Villacorta, Anne-Claude Gavin, Vladimir Benes, Simon Raffel, Anthony D Ho

Blood (2023) 142 (Supplement 1): 1323.

https://doi.org/10.1182/blood-2023-180830

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

Cell Cycle and Differentiation Arrest in Senescent Population of Human Hematopoietic Stem and Progenitor Cell Compartment

Laura Poisa-Beiro, Jonathan JM Landry, Simon Raffel, Volker Eckstein, Laura Villacorta, Anne-Claude Gavin, Vladimir Benes, Anthony D Ho

Blood (2022) 140 (Supplement 1): 5751–5752.

https://doi.org/10.1182/blood-2022-164547

Published: 2022

Journal Articles

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Blood (2022) 140 (Supplement 1): 121–123.

https://doi.org/10.1182/blood-2022-158934

Published: 2022

Journal Articles

Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia

Simon Renders, Alexander Waclawiczek, Aino-Maija Leppä, Cecilia Reyneri, Barbara Betz, Karolin Stumpf, Maike Janssen, Julia M. Unglaub, Elisa Donato, Rabia Shahswar, Simon Raffel, Michael Heuser, Richard F. Schlenk, Michael Hundemer, Tim Sauer, Carsten Müller-Tidow, Andreas Trumpp

Blood (2022) 140 (Supplement 1): 2023–2024.

https://doi.org/10.1182/blood-2022-164831

Published: 2022

Journal Articles

Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition

Simon Renders, Aino-Maija Leppä, Alexander Waclawiczek, Maike Janssen, Elisa Donato, Cecilia Reyneri, Julia M. Unglaub, Michael Hundemer, Richard F. Schlenk, Simon Raffel, Carsten Müller-Tidow, Tim Sauer, Andreas Trumpp

Blood (2021) 138 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2021-149781

Published: 2021

Journal Articles

Elevated Central Carbon Metabolism - a Hallmark for Senescent Cells in Aging Human Hematopoietic Stem Cell Compartment

Laura Poisa-Beiro, Jonathan Landry, Simon Raffel, Volker Eckstein, Anne-Claude Gavin, Motomu Tanaka, Vladimir Benes, Anthony D. Ho

Blood (2021) 138 (Supplement 1): 1088.

https://doi.org/10.1182/blood-2021-150761

Published: 2021

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, MD, Simon Raffel, MD, Ralph Wäsch, Sebastian Scholl, Mustafa Kondakci, MD, Andreas Rank, PD Dr, Mathias Haenel, MD, Sonja Martin, MD, Katjana Schwab, MD, Julian Knaden, Klaus Wethmar, MD, Tim Sauer, MD, Wolfgang E. Berdel, Prof., MD, Georg Lenz, Martin Dugas, Monika Brüggemann, MD, Nicola Goekbuget, MD, Nael Alakel, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-136920

Published: 2020

Journal Articles

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Blood (2020) 136 (13): 1507–1519.

https://doi.org/10.1182/blood.2019003654

Published: 2020

Includes: Supplemental data

Journal Articles

Characteristic Amino Acid and Energy Metabolism in AML Stem Cells As Revealed By Quantitative Multiplex Proteomics

Simon Raffel, MD, Jenny Hansson, Mattia Falcone, Christoph Lutz, Oliver Bischel, MD, Anthony D Ho, Jeroen Krijgsveld, Andreas Trumpp, Prof, PhD

Blood (2018) 132 (Supplement 1): 2780.

https://doi.org/10.1182/blood-2018-99-117046

Published: 2018

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

Blood (2017) 130 (Supplement 1): 472.

https://doi.org/10.1182/blood.V130.Suppl_1.472.472

Published: 2017

Journal Articles

In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations

Simon Raffel, MD, Jenny Hansson, PhD, Carl Herrmann, PhD, Christoph Lutz, MD, Eike C. Buss, MD, Christian Thiede, MD, Anne Floercken, MD, Oliver Bischel, MD, Joerg Westermann, MD, Gerhard Ehninger, MD, Anthony D Ho, MD, Roland Eils, PhD, Jeroen Krijgsveld, PhD, Andreas Trumpp, PhD

Blood (2014) 124 (21): 2144.

https://doi.org/10.1182/blood.V124.21.2144.2144

Published: 2014

NARROW

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Mechanisms of Aging Vary with Developmental Stages in the Human Hematopoietic Trajectory

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Cell Cycle and Differentiation Arrest in Senescent Population of Human Hematopoietic Stem and Progenitor Cell Compartment

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia

Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition

Elevated Central Carbon Metabolism - a Hallmark for Senescent Cells in Aging Human Hematopoietic Stem Cell Compartment

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells

Characteristic Amino Acid and Energy Metabolism in AML Stem Cells As Revealed By Quantitative Multiplex Proteomics

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only